-
2024-511457-22-00
3
2025-01-30
Advanced Hematologic Malignancies
-
2023-507717-94-00
5
2024-12-06
Deep partial and full-thickness burns
-
2023-507746-83-00
5
2024-11-27
Generalized Myasthenia Gravis
-
2024-512423-36-00
5
2024-11-20
Undifferentiated pleomorphic sarcoma
-
2024-511477-29-00
4
2024-11-08
Patients diagnosed with unresectable and / or metastatic locoregionall
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-503545-67-00
5
2024-04-30
Tourette's Disorder
-
2023-503290-38-00
4
2023-09-05
Bronchiectasis
-
2023-509710-11-00
4
2023-07-11
Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy
-
2022-500266-10-00
5
2023-06-13
Recessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epider
-
2024-512483-59-00
5
2023-06-09
Improvement of cardiovascular outcomes in patients with advanced
chron
-
2023-509810-13-00
4
2023-05-13
Acute Lymphoblastic Leukemia (ALL)
-
2023-507031-38-00
5
2023-01-09
Severe viral lung infections
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2023-507518-28-00
5
2022-09-13
Acute myeloid leukemia
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2023-509138-21-00
5
2021-08-26
Pulmonary Arterial Hypertension (PAH)
-
2023-510509-17-00
7
2020-06-17
Relapsed and/or refractory Acute Myeloid Leukemia
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
-
2024-520443-16-00
5
2026-05-04
Overweight or obesity, and obstructive sleep apnoea treated with posit
-
2024-520442-36-00
5
2026-04-30
Overweight or obesity, and obstructive sleep apnoea not treated with p
-
2025-523914-10-00
6
2026-04-30
Critical illness
-
2025-521560-36-00
4
2026-04-22
Type 1 Diabetes